Poppy L. A. Schoenberg, Emily M. Mohr, Phyllis E. Kilpatrick, Barbara A. Murphy
{"title":"非中枢神经系统癌症幸存者的神经认知障碍","authors":"Poppy L. A. Schoenberg, Emily M. Mohr, Phyllis E. Kilpatrick, Barbara A. Murphy","doi":"10.1027/0269-8803/a000326","DOIUrl":null,"url":null,"abstract":"Abstract: Cancer and its treatments entail a profound inflammatory response of the central nervous system (CNS). This intense neurotoxic process can lead to significant neurocognitive impairment even in non-CNS cancers. Few studies have examined this domain, and data available is based on limited designs using neuropsychological assessments comprising self-report or traditional testing batteries that capture basic response data. Here, we leverage cognitive electrophysiology, specifically Event-Related Potentials (ERPs), to examine and delineate neurocognitive impairments in non-CNS cancer survivors. Eleven survivors, who were on average 4.6 years in remission from head and neck cancer and 10 matched healthy controls underwent standardized cognitive and emotional “Go-Nogo” paradigms concomitant to EEG recording. Significant differences in amplitude morphology in the very early ERP components (C1, N1, P1) and middle ERP component (N2), were apparent between non-CNS cancer survivors and controls. Later ERP components (P3, N4) did not show amplitude differences. Non-CNS cancer survivors yielded faster latencies in the early components for pain-related stimuli during the emotional paradigm, albeit tended to yield slower ERP latencies overall across both experiments. These findings suggest that early gating and inhibitory control are dysregulated in non-CNS cancer survivors, which can impact executive functioning and cognitive processing involved in everyday activities for many years post-treatment. The findings do not fully align with ERP morphologies associated with neurocognitive impairment in degenerative conditions (such as dementia and Alzheimer’s disease), affecting later-stage ERP components. Our initial results suggest that (1) cognitive impairments in cancer survivors do not follow a degenerative trajectory, (2) rather are in line with “lesion” related damage (such as stroke, epilepsy), and as such, (3) have the potential for treatments involving neurocognitive plasticity.","PeriodicalId":50075,"journal":{"name":"Journal of Psychophysiology","volume":"60 1","pages":"0"},"PeriodicalIF":0.9000,"publicationDate":"2023-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Neurocognitive Impairment in Non-Central Nervous System Cancer Survivors\",\"authors\":\"Poppy L. A. Schoenberg, Emily M. Mohr, Phyllis E. Kilpatrick, Barbara A. Murphy\",\"doi\":\"10.1027/0269-8803/a000326\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract: Cancer and its treatments entail a profound inflammatory response of the central nervous system (CNS). This intense neurotoxic process can lead to significant neurocognitive impairment even in non-CNS cancers. Few studies have examined this domain, and data available is based on limited designs using neuropsychological assessments comprising self-report or traditional testing batteries that capture basic response data. Here, we leverage cognitive electrophysiology, specifically Event-Related Potentials (ERPs), to examine and delineate neurocognitive impairments in non-CNS cancer survivors. Eleven survivors, who were on average 4.6 years in remission from head and neck cancer and 10 matched healthy controls underwent standardized cognitive and emotional “Go-Nogo” paradigms concomitant to EEG recording. Significant differences in amplitude morphology in the very early ERP components (C1, N1, P1) and middle ERP component (N2), were apparent between non-CNS cancer survivors and controls. Later ERP components (P3, N4) did not show amplitude differences. Non-CNS cancer survivors yielded faster latencies in the early components for pain-related stimuli during the emotional paradigm, albeit tended to yield slower ERP latencies overall across both experiments. These findings suggest that early gating and inhibitory control are dysregulated in non-CNS cancer survivors, which can impact executive functioning and cognitive processing involved in everyday activities for many years post-treatment. The findings do not fully align with ERP morphologies associated with neurocognitive impairment in degenerative conditions (such as dementia and Alzheimer’s disease), affecting later-stage ERP components. Our initial results suggest that (1) cognitive impairments in cancer survivors do not follow a degenerative trajectory, (2) rather are in line with “lesion” related damage (such as stroke, epilepsy), and as such, (3) have the potential for treatments involving neurocognitive plasticity.\",\"PeriodicalId\":50075,\"journal\":{\"name\":\"Journal of Psychophysiology\",\"volume\":\"60 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2023-09-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Psychophysiology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1027/0269-8803/a000326\",\"RegionNum\":4,\"RegionCategory\":\"心理学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"NEUROSCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Psychophysiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1027/0269-8803/a000326","RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
Neurocognitive Impairment in Non-Central Nervous System Cancer Survivors
Abstract: Cancer and its treatments entail a profound inflammatory response of the central nervous system (CNS). This intense neurotoxic process can lead to significant neurocognitive impairment even in non-CNS cancers. Few studies have examined this domain, and data available is based on limited designs using neuropsychological assessments comprising self-report or traditional testing batteries that capture basic response data. Here, we leverage cognitive electrophysiology, specifically Event-Related Potentials (ERPs), to examine and delineate neurocognitive impairments in non-CNS cancer survivors. Eleven survivors, who were on average 4.6 years in remission from head and neck cancer and 10 matched healthy controls underwent standardized cognitive and emotional “Go-Nogo” paradigms concomitant to EEG recording. Significant differences in amplitude morphology in the very early ERP components (C1, N1, P1) and middle ERP component (N2), were apparent between non-CNS cancer survivors and controls. Later ERP components (P3, N4) did not show amplitude differences. Non-CNS cancer survivors yielded faster latencies in the early components for pain-related stimuli during the emotional paradigm, albeit tended to yield slower ERP latencies overall across both experiments. These findings suggest that early gating and inhibitory control are dysregulated in non-CNS cancer survivors, which can impact executive functioning and cognitive processing involved in everyday activities for many years post-treatment. The findings do not fully align with ERP morphologies associated with neurocognitive impairment in degenerative conditions (such as dementia and Alzheimer’s disease), affecting later-stage ERP components. Our initial results suggest that (1) cognitive impairments in cancer survivors do not follow a degenerative trajectory, (2) rather are in line with “lesion” related damage (such as stroke, epilepsy), and as such, (3) have the potential for treatments involving neurocognitive plasticity.
期刊介绍:
The Journal of Psychophysiology is an international periodical that presents original research in all fields employing psychophysiological measures on human subjects. Contributions are published from psychology, physiology, clinical psychology, psychiatry, neurosciences, and pharmacology. Communications on new psychophysiological methods are presented as well. Space is also allocated for letters to the editor and book reviews. Occasional special issues are devoted to important current issues in psychophysiology.